BACKGROUND: Hyperglycemia on admission is a predictor of unfavorable prognosis in patients with acute myocardial infarction (AMI). Data concerning associations between elevated glucose level on admission and other in-hospital complications are still limited. METHODS: A total of 607 AMI patients with complete admission glucose data in the Krakow Registry of Acute Coronary Syndromes were identified and were stratified according to glucose admission level. RESULTS: A total of 71.5% of patients were with admission glucose level <7.8 mmol/l, 17.6% of patients with 7.8-11.0 mmol/l, and 10.9% of patients with ≥11.1 mmol/l. In-hospital mortality for patients treated conservatively was higher in patients with higher admission glucose (8.0 vs. 25.0 vs. 39.1%, respectively, P < 0.0001), and significant mortality difference was confirmed both for diabetic and non-diabetic patients. Admission hyperglycemia was associated with increased risk of ventricular tachycardia/ventricular fibrillation, atrial fibrillation, second to third atriventricular block, pulmonary oeadema, but not ischemic stroke and blood transfusion during index hospital stay. CONCLUSIONS: Elevated admission glucose levels are associated with increased risk of life-threatening complications, especially arrhythmias in diabetic and non-diabetic AMI patients. This increased risk of complications is one of the possible explanations for the elevated in-hospital mortality in AMI patients presenting with hyperglycemia.
BACKGROUND:Hyperglycemia on admission is a predictor of unfavorable prognosis in patients with acute myocardial infarction (AMI). Data concerning associations between elevated glucose level on admission and other in-hospital complications are still limited. METHODS: A total of 607 AMI patients with complete admission glucose data in the Krakow Registry of Acute Coronary Syndromes were identified and were stratified according to glucose admission level. RESULTS: A total of 71.5% of patients were with admission glucose level <7.8 mmol/l, 17.6% of patients with 7.8-11.0 mmol/l, and 10.9% of patients with ≥11.1 mmol/l. In-hospital mortality for patients treated conservatively was higher in patients with higher admission glucose (8.0 vs. 25.0 vs. 39.1%, respectively, P < 0.0001), and significant mortality difference was confirmed both for diabetic and non-diabeticpatients. Admission hyperglycemia was associated with increased risk of ventricular tachycardia/ventricular fibrillation, atrial fibrillation, second to third atriventricular block, pulmonary oeadema, but not ischemic stroke and blood transfusion during index hospital stay. CONCLUSIONS: Elevated admission glucose levels are associated with increased risk of life-threatening complications, especially arrhythmias in diabetic and non-diabetic AMIpatients. This increased risk of complications is one of the possible explanations for the elevated in-hospital mortality in AMI patients presenting with hyperglycemia.
Authors: Markku S Nieminen; Michael Böhm; Martin R Cowie; Helmut Drexler; Gerasimos S Filippatos; Guillaume Jondeau; Yonathan Hasin; José Lopez-Sendon; Alexandre Mebazaa; Marco Metra; Andrew Rhodes; Karl Swedberg; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin R Cowie; Veronica Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; João Morais; Ali Oto; Otto A Smiseth; Maria Angeles Alonso Garcia; Kenneth Dickstein; Anibal Albuquerque; Pedro Conthe; Maria Crespo-Leiro; Roberto Ferrari; Ferenc Follath; Antonello Gavazzi; Uwe Janssens; Michel Komajda; João Morais; Rui Moreno; Mervyn Singer; Satish Singh; Michal Tendera; Kristian Thygesen Journal: Eur Heart J Date: 2005-01-28 Impact factor: 29.983
Authors: Alvaro Avezum; Marcia Makdisse; Frederick Spencer; Joel M Gore; Keith A A Fox; Gilles Montalescot; Kim A Eagle; Kami White; Rajendra H Mehta; Elias Knobel; Jean-Philippe Collet Journal: Am Heart J Date: 2005-01 Impact factor: 4.749
Authors: P Petursson; J Herlitz; K Caidahl; S Gudbjörnsdottir; T Karlsson; E Perers; H Sjöland; M Hartford Journal: Int J Cardiol Date: 2006-07-18 Impact factor: 4.164
Authors: Dariusz Dudek; Zbigniew Siudak; Marcin Kuta; Artur Dziewierz; Waldemar Mielecki; Tomasz Rakowski; Dawid Giszterowicz; Jacek S Dubiel Journal: Kardiol Pol Date: 2006-10 Impact factor: 3.108
Authors: Philippe Gabriel Steg; Robert J Goldberg; Joel M Gore; Keith A A Fox; Kim A Eagle; Marcus D Flather; Immad Sadiq; Rachel Kasper; Sophie K Rushton-Mellor; Frederick A Anderson Journal: Am J Cardiol Date: 2002-08-15 Impact factor: 2.778
Authors: Artur Dziewierz; Zbigniew Siudak; Tomasz Rakowski; Waldemar Mielecki; Dawid Giszterowicz; Jacek S Dubiel; Dariusz Dudek Journal: Coron Artery Dis Date: 2007-06 Impact factor: 1.439
Authors: Alvaro Avezum; Leopoldo S Piegas; Robert J Goldberg; David Brieger; Martin K Stiles; Richard Paolini; Wei Huang; Joel M Gore Journal: Am J Cardiol Date: 2008-10-23 Impact factor: 2.778
Authors: Paolo Gresele; Giuseppe Guglielmini; Massimiliano De Angelis; Silvia Ciferri; Marco Ciofetta; Emanuela Falcinelli; Carlo Lalli; Giovanni Ciabattoni; Giovanni Davì; Geremia B Bolli Journal: J Am Coll Cardiol Date: 2003-03-19 Impact factor: 24.094
Authors: Serdar Farhan; Rudolf Jarai; Ioannis Tentzeris; Alexandra Kautzky-Willer; Eslam Samaha; Peter Smetana; Gabriele Jakl-Kotauschek; Johann Wojta; Kurt Huber Journal: Clin Res Cardiol Date: 2012-03-06 Impact factor: 5.460
Authors: Abdullah Kaplan; Emna Abidi; Ahmed El-Yazbi; Ali Eid; George W Booz; Fouad A Zouein Journal: Heart Fail Rev Date: 2018-05 Impact factor: 4.214
Authors: Bi Huang; Xinjie Wang; Yanmin Yang; Jun Zhu; Yan Liang; Huiqiong Tan; Litian Yu; Xin Gao; Han Zhang; Juan Wang Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889